PND52 Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients  by Soini, E. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A399
Objectives: Health care resource utilization and costs were evaluated for patients 
diagnosed with multiple sclerosis (MS) in the U. S. Medicaid program. MethOds: 
Patients diagnosed with MS (International Classification of Disease, 9thRevision, 
Clinical Modification [ICD-9-CM] diagnosis code 340) were identified using Medicaid 
data from 01JAN2008 through 31DEC2010. The initial diagnosis date was designated 
as the index date. Patients of the same age, race, and gender but without an MS 
diagnosis were identified and matched as the comparison cohort, with a randomly 
chosen index date to minimize selection bias. Patients in both groups were required 
to be at least age 18 years, and have continuous medical and pharmacy benefits 
1 year before and 1 year post-index date. One-to-one propensity score matching 
(PSM) was used to compare health care costs and utilizations during the follow-up 
period, between the diseased and the comparison cohorts, and adjusted for baseline 
demographic and clinical characteristics. Results: After risk adjustment by PSM, a 
total of 14,179 patients in each cohort were matched. Significantly more MS patients 
had inpatient admissions (23.75% vs. 10.87%, p< 0.0001) and long-term care (22.64% 
vs. 4.13%, p< 0.0001), other service (99.70% vs. 89.00%, p< 0.0001) and pharmacy visits 
(73.08% vs. 67.71%, p< 0.0001) compared to those without an MS diagnosis. Higher 
health care utilization by MS patients led to significantly higher inpatient ($1,688 
vs. $725, p< 0.0001), long-term care ($14,189 vs. $2,778, p< 0.0001), other service visit 
($22,981 vs. $9,977, p< 0.0001) and pharmacy costs ($5,284 vs. $1,785, p< 0.0001) com-
pared to those without MS. cOnclusiOns: Compared to patients in the comparator 
cohort, MS patients in the Medicaid program incurred substantially higher health 
care resource utilization and costs.
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Objectives: CUA of teriflunomide and first-line DMTs (glatiramer acetate (GA), 
interferon-β -1a (IFNβ -1a: intramuscular IM, or subcutaneous SC) or interferon-β -1b 
(IFNβ -1b)), compared to BSC in Finnish RRMS-patients. MethOds: Register study 
and Markov cohort modelling. During the 50-year time horizon, patients could stay 
or progress to another Expanded Disability Status Scale (EDSS) state, experience 
relapse (with/without hospitalisation), adverse events (AEs) or death. EQ-5D utili-
ties were derived from literature, and Finnish costs (health care 2013; official drug 
costs 4/2014 without VAT) were associated with EDSS, relapses, and AEs. Indirect 
treatment comparison informed treatment effects. EDSS-related standardised mor-
tality ratios (SMR) and RRMS-progression were analysed from Finnish MS-register 
(Tampere, Vaasa, Seinäjoki regions; 1359 patients). Other health risks were based 
on literature. Cohort characteristics were estimated from a subgroup (713 patients, 
clinically confirmed RRMS, age, gender and EDSS 0–6.5 at first DMT initiation). 
Caregiver’s disutility, Finnish productivity losses, and informal care costs were 
included in sensitivity analysis (societal perspective). Costs and quality-adjusted 
life-years (QALYs) were discounted with 3%/year. Results: Expected lifetime health 
care [societal] costs per patient were: teriflunomide: € 798,864 [€ 1,596,570], IFNβ -1a-
SC: € 805,069 [€ 1,618,344], IFNβ -1b: € 826,633 [€ 1,647,745], GA: € 823,438 [€ 1,649,961], 
IFNβ -1a-IM: € 820,516 [€ 1,645,472], and BSC: € 788,932 [€ 1,626,554]. Respective QALYs 
were 6.55 [5.44], 6.27 [5.13], 6.15 [4.99], 6.05 [4.88], 6.04 [4.87], and 5.79 [4.60]. From 
the payer [societal] perspective, incremental cost per QALY gained of teriflunomide 
was € 13,089 [dominant] relative to BSC, and teriflunomide dominated other first-
line DMTs. Teriflunomide had 83% [per-patient expected value of perfect informa-
tion, EVPI € 241], 98% [EVPI € 22], and 100% [EVPI € 0] cost-effectiveness probability 
with € 0, € 10,000, and € 20,000 per additional QALY, respectively. cOnclusiOns: 
Cost-effectiveness analyses of first-line DMTs compared to BSC showed that teri-
flunomide provided lowest cost and highest number of QALYs and was therefore 
dominant over IFNβ s and GA for Finnish RRMS patients.
PND53
Cost-effeCtiVeNess MoDel resUlts of iNtrAtheCAl BAClofeN therAPy 
CoMPAreD to CoNVeNtioNAl MeDiCAl MANAgeMeNt iN PAtieNts with 
NoN-foCAl DisABliNg sPAstiCity who Are resistANt or iNtolerANt to 
orAl therAPy At the iNstitUt gUttMANN
Slof J.1, Serrano D.2, Álvarez M.3, Álvarez López-Dóriga M.3, Marqués T.4, Benito J.4, Vidal J.4
1Universitat Autònoma de Barcelona, Bellaterra, Spain, 2Autonomous Consultant, Barbera del 
Valles, Spain, 3Medtronic Ibérica, S.A., Madrid, Spain, 4Institut Guttmann, Barcelona, Spain
Objectives: To estimate the cost-effectiveness of intrathecal baclofen ther-
apy (ITB) against conventional medical management (CMM) in non-focal 
disabling spasticity (N-FDS) patients who are resistant or intolerant to oral ther-
apy. MethOds: A markov model was developed to estimate clinical and economic 
outcomes for patients treated with ITB or CMM. Treatment effects, patients´ base-
line characteristics, resource utilization and health utility values were taken from 
the EPICE study. The model was built in accordance with the Institut Guttmann´s 
clinical practice, a reference center in Spain. Unit costs were obtained from the 
cited center. The analysis was conducted from the Institut Guttmann´s perspec-
tive over a lifetime horizon with direct medical costs (2013) and outcomes dis-
counted at 3%. Uncertainty was assessed through univariate and multivariate 
sensitivity analysis (SA). Results: When comparing ITB with CMM, the model 
estimates ITB would increase remaining lifetime costs by € 35,605 and result in a 
QALY gain of 1.06; thus showing an incremental cost-effectiveness ratio (ICER) of 
€ 33,619 per QALY gained. SA reflecting the most current clinical practice at the 
Institut Guttmann (where now a new catheter, associated with an 80% reduction 
in adverse events, is used) showed an ICER of € 27,805 per QALY gained. ICER 
results were also sensitive to changes in the post-operation hospitalization period, 
baclofen dose titration management, pump battery life, and health utility val-
ues. cOnclusiOns: The present evaluation results in an ICER of ITB against CMM, 
in the treatment of N-FDS patients who are resistant or intolerant to oral therapy 
at the Institut Guttmann, close to a willingness-to-pay threshold of € 30,000 per 
states: Expanded Disability Status Scale (EDSS) 0-9 for patients with RRMS and 
secondary progressive multiple sclerosis (SPMS), respectively, and death (EDSS10). 
Total treatment costs, quality-adjusted life-years (QALYs) gained and incremental 
cost-effectiveness ratios (ICERs) were calculated from the Dutch societal perspec-
tive. Baseline demographics; transition probabilities; treatment-specific relative 
risks; and utility values were obtained from published literature. Health resource 
use was based on the products’ SmPCs. Unit costs were based on national tar-
iffs and published data. A base case analysis considered the direct and indirect 
costs of treatment. To test the robustness of the results, univariate and probabil-
istic sensitivity analyses (PSA) were performed. Results: Total treatment costs 
of glatiramer acetate were lower versus teriflunomide, interferon-beta-1a 44mcg, 
30mcg, fingolimod, natalizumab, dimethyl fumarate and alemtuzumab; and higher 
versus interferon-beta-1a 22mcg, interferon-beta-1b, and BSC. Glatiramer acetate 
dominated interferon-beta-1a 44mcg and 30mcg, and was cost-effective versus 
other comparators at a willingness-to-pay threshold of € 20,000/QALY. The PSA 
indicated these results were robust. Univariate analysis showed that relative risks 
of disease progression and drug costs were the most influential model param-
eters. cOnclusiOns: In the Netherlands, glatiramer acetate is a cost-effective 
treatment versus a number of other treatments indicated in multiple sclerosis, 
and results proved robust.
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Objectives: To calculate the expected value of partial perfect information (EVPPI) 
of the disability progression efficacy for teriflunomide and fingolimod in relapsing-
remitting multiple sclerosis (RRMS) and investigate the potential differences between 
these two disease modifying therapies (DMTs). MethOds: A cohort Markov model 
based on the ScHARR model structure was developed from the UK NHS perspective, 
which allows the cost-effectiveness of the DMTs to be calculated and also has the 
additional ability to calculate the EVPPIs for progression efficacies. The evaluated 
intervention consists of beta-interferons followed by fingolimod. The comparator 
treatment includes beta-interferon therapy followed by teriflunomide. The EVPPIs 
for both drugs were calculated and compared. Results: The EVPPIs varied substan-
tially depending on the evaluated drug and the specific willingness-to-pay (WTP). 
Although both EVPPI curves had a similar shape, the curve for teriflunomide had an 
EVPPI equal or larger compared to fingolimod’s curve for every WTP value. At a WTP 
of £30,000 per QALY, the EVPPI per patient of teriflunomide and fingolimod were 
£252 and £50, respectively. In the sensitivity analysis, where the uncertainty around 
the estimate of teriflunomide progression efficacy was artificially lowered to that of 
fingolimod, the divergence between the EVPPI curves was reduced substantially, con-
firming that the uncertainty around teriflunomide progression efficacy is driving its 
higher EVPPI. cOnclusiOns: Higher EVPPI estimates of teriflunomide indicate that 
the precise knowledge of the disability progression efficacy of teriflunomide would 
be considerably more valuable to the decision maker than that of fingolimod. One 
of the main factors affecting larger EVPPI of teriflunomide’s progression efficacy is a 
higher uncertainty concerning effects of teriflunomide. There are, however, many data 
limitations and uncertainties within the DMT modelling. Additionally, the expected 
value of sample information analysis (EVSI) would be required in order to evaluate 
more precisely the cost-effectiveness of additional clinical trials.
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Objectives: Colistimethate sodium (Colistin) is an old, “forgotten” antibiotics 
revived due to multidrug-resistant Gram-negative bacteria in nosocomial infec-
tions. In many countries, both – intravenous and inhalational administrations of 
Colistin have marketing authorisation. In Serbia, Colistin is registered only for 
intravenous administration. Therefore, inhalational administration of Colistin in 
treatment for cystic fibrosis is considered as off label use. AiM: The purpose of 
this study was to assess benefits of Colistin off label use, currently available in 
Serbia, for treatment for cystic fibrosis. MethOds: Data collected from a review 
of the literature (Pubmed searching key word off label, Colistin, Tobramycine, cost 
minimisation) and data from Health Insurance Fond of Republic Serbia (2014) 
were used to perform a cost-minimisation analysis comparing DDD in inhalation 
administration of Colistin with Tobramycin (official methodology in Serbia for drug 
reimbursement Listing). Results: Both, Colistin and Tobramycine are effective 
in cystic fibrosis treatment. The cost of treatment per patient per year in Serbia is 
3 616,00 Euro for Colistin and 5 950,00 Euro for Tobramycin. Total savings per year 
for 200 registered patients in Serbia could be 466 857,00 Euro. cOnclusiOns: 
Given cost-minimisation analysis justified the treatment with Colistin as cost 
saving therapeutic alternative to Tobramycin for cystic fibrosis patients in Serbia. 
The lack of guidelines and principles regarding off label medicine use in health 
care policy and decision making in Serbia was evidently an obstacle for better 
patients care.
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